CD274 and non-small cell lung carcinoma: Durvalumab injection (hereinafter referred to as Durvalumab), the first approved PD-L1 inhibitor in China, is a fully humanized IgG1 monoclonal antibody against PD-L1 which has been recommended as a consolidation therapy following concurrent chemoradiotherapy for patients with unresectable stage III NSCLC by National Comprehensive Cancer Network (NCCN) guidelines, European Society for Medical Oncology (ESMO) guidelines and the Chinese Society of Clinical Oncology (CSCO) guidelines [6–8].